Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bedoradrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bedoradrine SCHEMBL29379919 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL7586092 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828783 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL10026405 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694818 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694819 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL678131 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29385851 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL1261689 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| SCHEMBL7585377 | 0.94 | ADRB1 (0.64) | ADRB1ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098511-A1 | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring | Solvias AG (CH) | 2009-09-09 | — | — | EP | claimed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20140056999-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140056999-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8420697-B2 | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | MEDICINOVA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120295982-A1 | TREATING HUMAN MALE COPD PATIENTS WITH ORAL BEDORADRINE | MEDICINOVA, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120251632-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251632-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20110117213-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110117213-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009109648-A1 | PROCESS FOR PREPARING COMPOUNDS CONTAINING A HYDRONAPHTALENE STRUCTURE WITH AN UNSYMMETRICALLY SUBSTITUTED BENZENE RING | SOLVIAS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| EP-2098511-A1 | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring | Solvias AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-0882704-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6133266-A | 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0882704-A1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140056999-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | CHRM3, CHRM2, CHRM5 | ADRB2 21/4885ADRB1 31/4885ADRB3 12/4885 |
| US-20120251632-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | CHRM3, CHRM2, CHRM5 | ADRB2 21/4885ADRB1 31/4885ADRB3 12/4885 |
| US-20110117213-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | CHRM3, CHRM2, CHRM5 | ADRB2 21/4885ADRB1 31/4885ADRB3 12/4885 |
| US-20120295982-A1 | TREATING HUMAN MALE COPD PATIENTS WITH ORAL BEDORADRINE | ALG3, RFT1, SLC14A1 | ADRB2 328/4885ADRB1 387/4885ADRB3 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.